Why rate of absorption inferences in single dose bioequivalence studies are often inappropriate

被引:14
作者
Basson, RP [1 ]
Ghosh, A [1 ]
Cerimele, BJ [1 ]
DeSante, KA [1 ]
Howey, DC [1 ]
机构
[1] Eli Lilly & Co, Lilly Lab Clin Res, Indianapolis, IN 46285 USA
关键词
bioequivalence; absorption rate; Tmax; absorption process rate; measurement theory; inference;
D O I
10.1023/A:1011974803996
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Peak drug concentration (C-max) measures the extremity of drug exposure and is a secondary indicator of the extent of absorption after area under the concentration time curve (AUC). C-max serves as the indicator of absorption rate in bioequivalence (BE) studies in the US (1). The use of C-max, not the time to C-max(T-max), as the metric to assess absorption rate causes erratic inferences in BE studies, and incorrect conclusions for some. We can improve BE efficiency (i.e., get the answer right the first time), by properly analyzing the time to C-max(T-max) instead of C-max. Methods. We have previously redirected attention to T-max as the unconfounded absorption rate variable, instead of C-max, and have called for equally spaced sampling times during the suspected absorption phase to improve the performance of the rate metric (2). Equal spacing converts T-max easily into a count variable and we illustrated an appropriate statistical analysis for counts. This paper provides some measurement theory concepts to help judge which is the more appropriate analysis, and also provides parametric confidence limits for T-max treatment differences. Three separate BE studies are then analyzed by both methods. Results. By focusing on the differences in conclusions, or inferences, this paper identifies three major issues with the current FDA "recommended" analysis of BE studies. First, C-max, a continuous variable peak-height or extent measure has usurped T-max's function and performs erratically as a substitute measure for the rate of absorption. Second, T-max, should be analyzed as a discrete attribute, not as a continuous variable. Third, since several extent measures (AUC, C-max), not one, are actually being analyzed, an adjustment for multiple testing is mandatory if we are to maintain the size of the test at the desired a level (13). and not inadvertently use a narrower bioequivalence window than is intended. These actions all can have serious unintended consequences on inferences, including making inappropriate ones.
引用
收藏
页码:276 / 279
页数:4
相关论文
共 13 条
[1]   Tmax: An unconfounded metric for rate of absorption in single dose bioequivalence studies [J].
Basson, RP ;
Cerimele, BJ ;
Desante, KA ;
Howey, DC .
PHARMACEUTICAL RESEARCH, 1996, 13 (02) :324-328
[2]  
*CYT SOFTW COR, 1991, STATX STAT SOFTW EX, pCH4
[3]  
FELLER W, 1957, INTRO PROBABILITY TH, P135
[4]  
McCullagh P., 1989, GEN LINEAR MODELS, DOI [DOI 10.1007/978-1-4899-3242-6, 10.1201/9780203753736, DOI 10.2307/2347392]
[5]  
SARLE WS, 1995, MEASUREMENT THEORY F, V1, P61
[6]  
*SAS I, 1992, SAS TECHN REP SAS ST, P371
[7]  
*SAS I INC, 1993, SAS STAT SOFTW GENMO, P1
[8]  
*SAS I INC, 1988, SAS STAT US GUID, P549
[9]   A COMPARISON OF THE 2 ONE-SIDED TESTS PROCEDURE AND THE POWER APPROACH FOR ASSESSING THE EQUIVALENCE OF AVERAGE BIOAVAILABILITY [J].
SCHUIRMANN, DJ .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1987, 15 (06) :657-680
[10]  
SCHULZ HU, 1992, INT J CLIN PHARM TH, V30, pS1